Aytu BioPharma to Report First Quarter Fiscal 2023 Financial Results on November 14, 2022
Aytu BioPharma (Nasdaq: AYTU) will announce its first quarter fiscal year 2023 financial results after the market closes on November 14, 2022. A conference call to discuss these results is scheduled for the same day at 4:30 pm ET. Investors can join the call by dialing (877) 545-0523 or (973) 528-0016, using access code 883834. The call will also be available via webcast, with an archive lasting 90 days. Aytu's product portfolio includes prescription drugs for ADHD and a variety of consumer health products.
- Schedule for announcing Q1 FY2023 results could indicate ongoing transparency.
- Diverse product range addressing pediatric health and various allergies.
- None.
ENGLEWOOD, CO / ACCESSWIRE / November 7, 2022 / Aytu BioPharma, Inc. (the Company or "Aytu") (Nasdaq:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, will report financial results for its first quarter fiscal year 2023, ended September 30, 2022, after the market close on Monday, November 14, 2022. The Company has scheduled a conference call that same day, Monday, November 14, 2022, at 4:30 pm ET, to review the results.
Conference Call Information
Date and Time: Monday, November 14, 2022, at 4:30 pm ET
Call-in Information: Interested parties can access the conference call by dialing (877) 545-0523 or (973) 528-0016 using the participant access code 883834.
Webcast Information: The webcast will be accessible live and archived at the following link, https://www.webcaster4.com/Webcast/Page/2142/46981 and on Aytu BioPharma's website, within the Investors section under Events & Presentations, at aytubio.com, for 90 days.
Replay: A teleconference replay of the call will be available until November 28, 2022 at (877) 481-4010 or (919) 882-2331, replay access code 46981.
About Aytu BioPharma, Inc.
Aytu BioPharma is a pharmaceutical company commercializing a portfolio of commercial prescription therapeutics and consumer health products. The Company's prescription products include Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of attention deficit hyperactivity disorder (ADHD), as well as Karbinal® ER (carbinoxamine maleate), an extended-release antihistamine suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor® and Tri-Vi-Flor®, two complementary fluoride-based prescription vitamin product lines available in various formulations for infants and children with fluoride deficiency. Aytu's consumer health segment markets a range of over-the-counter medicines, personal care products, and dietary supplements addressing a range of common conditions including diabetes, allergy, hair regrowth, and gastrointestinal conditions. To learn more, please visit aytubio.com.
Contacts for Investors:
Mark Oki, Chief Financial Officer
Aytu BioPharma, Inc.
moki@aytubio.com
Robert Blum or Roger Weiss
Lytham Partners
AYTU@lythampartners.com
SOURCE: Aytu BioPharma, Inc.
View source version on accesswire.com:
https://www.accesswire.com/723977/Aytu-BioPharma-to-Report-First-Quarter-Fiscal-2023-Financial-Results-on-November-14-2022
FAQ
When will Aytu BioPharma report its financial results for Q1 FY2023?
What time is Aytu BioPharma's conference call regarding Q1 FY2023 results?
How can investors access Aytu BioPharma's conference call?
Will there be a webcast for Aytu BioPharma's financial results announcement?
